Rationale for Selective COMT Inhibitors as Adjuncts in the Drug Treatment of Parkinson's Disease
- 1 May 1990
- journal article
- review article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 66 (5), 317-323
- https://doi.org/10.1111/j.1600-0773.1990.tb00756.x
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- The Promise and Limitations of Controlled-Release Oral Levodopa AdministrationClinical Neuropharmacology, 1989
- QSAR and Binding Model for Inhibition of Rat Liver Catechol-O-Methyl-Transferase by 1,5-Substituted-3,4-DihydroxybenzenesQuantitative Structure-Activity Relationships, 1989
- Catechol-O-methyltransferase activity in human and rat small intestineLife Sciences, 1988
- Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferaseLife Sciences, 1988
- Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 1987
- 3‐O‐Methyldopa and the response to levodopa in Parkinson's diseaseAnnals of Neurology, 1987
- The pharmacology of Parkinson's disease: Basic aspects and recent advancesCellular and Molecular Life Sciences, 1984
- 3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatumAnnals of Neurology, 1982
- 3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrierLife Sciences, 1975
- Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissuesLife Sciences, 1973